Hydrosoluble fiber (Plantago ovata husk) and levodopa II: Experimental study of the pharmacokinetic interaction in the presence of carbidopa

European Neuropsychopharmacology

Volumn 15, Issue 5, 2005, Pages 505-509

  Fernandez, Nelida ^a   Carriedo, Demetrio ^a   Sierra, Matilde ^a   Diez, M Jose ^a   Sahagun, Ana ^a   Calle, Angela ^a   Gonzalez, Aranzazu ^a   Garcia, Juan J ^a  

^a UNIVERSITY OF LEÓN   (Spain)

Author keywords

Carbidopa; Fiber; Levodopa; Pharmacokinetics; Plantago ovata husk; Rabbits

Indexed keywords

CARBIDOPA PLUS LEVODOPA; HERBACEOUS AGENT; PLANTABEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG POTENTIATION; NONHUMAN; PLANT FIBER; PLANTAGO OVATA; PRIORITY JOURNAL; RABBIT; SEED HUSK;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; CARBIDOPA; DIETARY FIBER; LEVODOPA; METABOLIC CLEARANCE RATE; MODELS, ANIMAL; MODELS, BIOLOGICAL; PHYTOTHERAPY; PLANTAGO; RABBITS;

EID: 24044516830     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2005.01.006     Document Type: Article

References (31)

1. Y. Agid, C.W. Olanow, and Y. Mizuno Levodopa: why the controversy? Lancet 360 2002 575
2. I. Anderson, A.K. Granerus, R. Jagenburg, and A. Svanborg Intestinal decarboxylation of orally administered l-dopa: influence of pharmacological preparations, dose magnitude, dose sequence and food intake Acta Med. Scand. 198 1975 415 420
3. E. Bredberg, H. Lennernas, and L. Paalzow Pharmacokinetics of levodopa and carbidopa in rats following different routes of administration Pharm. Res. 11 1994 549 555
4. E. Bredberg, J. Tedroff, S.M. Aquilonius, and L. Paalzow Pharmacokinetics and effects of levodopa in advanced Parkinson's disease Eur. J. Clin. Pharmacol. 39 1990 385 389
5. T.N. Chase, T.M. Engber, and N.M. Mouradian Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinsońs disease Neurology 44 1994 S15 S18
6. M. Contin, R. Riva, P. Martinelli, G. Procaccianti, P. Cortelli, P. Avoni, and A. Baruzzi Response to a standard oral levodopa test in Parkinsonian patients with and without motor fluctuations Clin. Neuropharmacol. 13 1990 19 28
7. M. Contin, R. Riva, P. Martinelli, P. Cortelli, F. Albani, and A. Baruzzi Pharmacodynamic modelling of oral levodopa: clinical application in Parkinson's disease Neurology 43 1993 367 371
8. D. Deleu, S. Sarre, G. Ebinger, and Y. Michotte In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle: a microdialysis study Naunyn-Schmiedeberg's Arch. Pharmacol. 344 1991 514 519
9. R. Djaldetti, M. Koren, I. Ziv, A. Achiron, and E. Melamed Effect of cisapride on response fluctuations in Parkinson's disease Mov. Disord. 10 1995 81 84
10. N. Fernández, J.J. García, M.J. Diez, A. Sahagun, A.P. Calle, and M. Sierra Improvement of the oral absorption of levodopa in the presence of psyllium Methods Find. Exp. Clin. Pharmacol. 25 2003 168
11. W.R. Garnett Gastrointestinal dysmotility and central nervous system disorders: use of cisapride in patients with Parkinson's disease Consult. Pharm. 11 1996 10 16
12. M. Gibaldi, and D. Perrier Multicompartment models, Pharmacokinetics 2nd ed. 1982 Marcel Dekker New York
13. A. Grahnen, S.A. Eckerna, C. Collin, A. Ling-Andersson, G. Tiger, and M. Nilsson Comparative multiple-dose pharmacokinetics of controlled-release levodopa products Eur. Neurol. 3 1992 343 348
14. S. Grange, N.H. Holford, and T.W. Guentert A pharmacokinetic model to predict the PK interaction of l-dopa and benserazide in rats Pharm. Res. 18 2001 1174 1184
15. W.E. Hansen Effect of dietary fiber on proteolytic pancreatic enzymes in vitro Int. J. Pancreatol. 1 1986 341 351
16. P. Hietala, I.B. Linden, and N. Gronfors The effect of simultaneous administration of 3,4-dihydroxyphenylpyruvic acid and l-dopa on the bioavailability of l-dopa in rat and mouse J. Pharm. Pharmacol. 31 1979 205 208
17. N.D. Huebert, M.G. Palfreyman, and K.D. Haegele A comparison of the effects of reversible and irreversible inhibitors of aromatic l-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral l-3,4-dihydroxyphenylalanine Drug Metab. Dispos. 11 1986 195 200
18. G. Isaksson, I. Lundquist, and I. Ihse Effect of dietary fiber on pancreatic enzyme activity in vitro Gastroenterology 82 1982 918 924
19. E. Leng-Peschlow Plantago ovata seeds as dietary fibre supplement, physiological and metabolic effects in rats Br. J. Nutr. 66 1991 331 349
20. P.S. Leppert, M. Cortese, and J.A. Fix The effects of carbidopa dose and time and route of administration on systemic l-dopa levels in rats Pharm. Res. 5 1988 587 591
21. I.B. Linden Effects of 3,4-dihydroxyphenylpyruvic acid and l-glutamic acid on some pharmacokinetic parameters of l-dopa in the rat J. Pharm. Pharmacol. 32 1980 344 348
22. M.M. Mouradian, I.J. Heuser, F. Baronti, and T.N. Chase Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinsońs disease Ann. Neurol. 27 1990 18 23
23. M.V. Nelson, R.C. Berchou, P.A. Lewitt, D. Kareti, N. Kesaree, P. Schlick, and M.P. Galloway Pharmacokinetic and pharmacodynamic modeling of l-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet Clin. Neuropharmacol. 12 1989 91 97
24. J.G. Nutt Levodopa-induced dyskinesia: review, observations, and speculations Neurology 40 1990 340 345
25. J.G. Nutt, W.R. Woodward, J.P. Hammerstad, J.H. Carter, and J.L. Anderson The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport N. Engl. J. Med. 310 1984 483 488
26. J.G. Nutt, and J.H. Fellman Pharmacokinetics of levodopa Clin. Neuropharmacol. 7 1984 35 49
27. D. Nyholm, H. Lennernas, C. Gomes-Trolin, and S.M. Aquilonius Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations Clin. Neuropharmacol. 25 2002 89 96
28. G.H.M. Paalzow, and L.K. Paalzow l-dopa: how it may exacerbate Parkinsonian symptoms TIPS 9 1986 15 19
29. R.M. Pinder, R.N. Brogden, P.R. Sawyer, T.M. Speight, and G.S. Avery Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of Parkinsonism Drugs 11 1976 329 377
30. L. Rivera-Calimlim, C.A. Dujovne, J.P. Morgan, L. Lasagna, and J.R. Bianchine l-dopa treatment failure: explanation and correction Br. Med. J. 10 1970 93 94
31. J.I. Sage, M.H. Mark, D.M. McHale, P.K. Sonsalla, and D. Vitagliano Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug-induced chorea Ann. Neurol. 29 1991 623 628